A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma

Melanoma Stage IV Clinical Trial

Official title:

A Phase II Study of Combination Treatment With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Japanese Patients With Stage IIIB, IIIC, or IV Unresectable or Metastatic Malignant Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03153085
• Other study ID #: TBI1401-02
• Status: Completed
• Phase: Phase 2
• Start date: May 25, 2017
• Est. completion date: December 14, 2018

Study information

• Verified date: March 2020
• Source: Takara Bio Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.

Description:

The study is designed to assess efficacy and safety with repeated administration of intratumoral injections of TBI-1401(HF10) at 1x10^7 TCID50/mL in combination with intravenous infusions of 3mg/kg ipilimumab in Japanese patients.

This is a single arm, open label Phase II study, to evaluate the efficacy and safety of TBI-1401(HF10) treatment in combination with the immunologic checkpoint inhibitor, ipilimumab (anti-CTLA-4 monoclonal antibody). The study population will include patients with Stage IIIB, IIIC or IV unresectable or metastatic malignant melanoma who are ipilimumab-eligible.

Patients will receive the dose of 1x10^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) + ipilimumab at 3 mg/kg (for a total of 4 intravenous infusions, each administered at 3-week intervals).

Following combination therapy, patients may continue to receive the 1x10^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if they have tolerated the study treatment, are responding, have stable disease, or have progressive disease that is not clinically significant in the judgment of the Investigator.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: December 14, 2018
• Est. primary completion date: June 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Patients with histologically confirmed Stage IIIB, IIIC or IV unresectable or metastatic melanoma except uveal melanoma, who must have a history of treatment (chemotherapy, molecular targeted therapy, or anti PD-1 antibody therapy).

• Patients must have measurable non-visceral lesion(s) that are evaluable by the modified World Health Organization (mWHO) criteria and immune-related response criteria (irRC).

• Patients must be = 20 years of age.

• Patients must have a life expectancy = 24 weeks.

• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• Patients must have adequate organ function, defined as

• Total bilirubin levels = 1.5 x upper limit of normal [ULN] (except for patients with Gilbert's Syndrome, who must have a total bilirubin of less than 3.0 mg/dL)

• AST/ALT levels = 2.5 x ULN, or = 5 x ULN if liver metastases are present.

• Creatinine = 1.5 x ULN or creatinine clearance (calculated) = 60 mL/min/1.73 m^2 for patients with creatinine > 1.5 x ULN.

• Absolute neutrophil count =1,500/µL and

• Platelet count = 75,000/ µL

• Men and women of childbearing potential must agree to use adequate contraception from the time of consent through 30 days after final study treatment.

• Females of childbearing potential must have a negative urine or serum pregnancy test within 1 week prior to start of treatment.

• Patients must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria:

• Patients who were previously treated with ipilimumab by intravenous infusion.

• Patients receiving chemotherapy or molecularly targeted drug or anti-PD-1 antibody treatment or radiotherapy or immunotherapy within 4 weeks prior to initiating study treatment.

• Patients with a history of Grade 4 adverse events caused by chemotherapy, molecularly targeted drug, anti-PD-1 antibody treatment, radiotherapy or immunotherapy conducted more than 4 weeks prior to TBI-1401(HF10) treatment, or presence of such adverse events of Grade 2 or greater, except alopecia and adverse events controlled by a treatment.

• Patients receiving anti-herpes medication within 1 week prior to initiating TBI-1401(HF10) administration, except local treatment such as ointment.

• Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.

• Patients with target tumors that could potentially invade a major vascular structure (e.g., innominate artery, carotid artery), based on unequivocal imaging findings.

• Patients with Grade 2 or greater neurologic abnormalities (CTCAE version 4.0), including Grade 2 or greater peripheral neuropathy caused by previous treatments.

• Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection.

• Patients requiring systemic glucocorticoid (except 10 mg/day/body prednisolone or less) or immunosuppressive therapy because of the presence or history of autoimmune disease (e.g., Crohn's disease, ulcerative colitis) or other diseases.

• Concurrent use of any other investigational agents within 4 weeks prior to initiating study treatment.

• Patients with active CNS metastases or carcinomatous meningitis, except patients with CNS lesions that have been treated and have no evidence of progression in the brain on CT/MRI for = 3 months.

• Pregnant or breastfeeding women (excluding the case in which breastfeeding is discontinued and will not resume it); women desiring to become pregnant within the timeframe of the study are also excluded.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.

Related Conditions & MeSH terms

• Melanoma
• Melanoma Stage III
• Melanoma Stage IV

Intervention

Biological:
• TBI-1401(HF10)
1x10^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals). Following combination therapy, patients may continue to receive the 1x10^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration.

Drug:
• Ipilimumab
3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).

Locations

Country	Name	City	State
Japan	Clinical Site	Chuo	Yamanashi
Japan	Clinical Site	Chuoku	Tokyo
Japan	Clinical Site	Fukuoka
Japan	Clinical Site	Kumamoto
Japan	Clinical Site	Kurume	Fukuoka
Japan	Clinical Site	Nagakute	Aichi
Japan	Clinical Site	Nagoya	Aichi
Japan	Clinical Site	Niigata
Japan	Clinical Site	Osaka
Japan	Clinical Site	Sapporo	Hokkaido
Japan	Clinical Site	Shizuoka
Japan	Clinical Site	Tsukuba	Ibaraki

Sponsors (1)

Lead Sponsor	Collaborator
Takara Bio Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Levels of antibody to HSV-1	Evaluate the change of anti-HSV-1 antibody levels.	up to weeks 24
Other	Change in immunologic parameters in serum	Analysis the change of cytokine profiles, antitumor T-cell reactivity and regulatory T-cell (Treg) population by immunoassay and flow cytometry.	up to weeks 24
Other	Histopathological response with TBI-1401(HF10) administrated tumor	Biopsies will be performed to evaluate the histopathological response with TBI-1401(HF10) administrated tumor.	up to weeks 24
Primary	Best overall response rate (BORR) by irRC	Determine the efficacy of TBI-1401(HF10) in combination with Ipilimumab evaluated by irRC (immuno-related response criteria)	at 24 weeks
Secondary	Best overall response rate (BORR) by mWHO response criteria	Determine the efficacy of TBI-1401(HF10) in combination with Ipilimumab evaluated by modified WHO (mWHO) response criteria	at weeks 24
Secondary	Best overall response rate (BORR) by RECIST version 1.1	Determine the efficacy of TBI-1401(HF10) in combination with Ipilimumab evaluated by RECIST version 1.1	at weeks 24
Secondary	Objective response rate (ORR) by irRC	Overall tumor response evaluated by irRC in the measurable target lesion(s) and unmeasurable/evaluable target lesion(s).	at weeks 6, 12, 18, and 24
Secondary	Objective response rate (ORR) by mWHO	Overall tumor response evaluated by mWHO response criteria in the measurable target lesion(s) and unmeasurable/evaluable target lesion(s).	at weeks 6, 12, 18, and 24
Secondary	Objective response rate (ORR) by RECIST version 1.1	Overall tumor response evaluated by RECIST version 1.1 in the measurable target lesion(s) and unmeasurable/evaluable target lesion(s).	at weeks 6, 12, 18, and 24
Secondary	Adverse event summaries, vital signs, and laboratory parameters to evaluate the safety and tolerability.	Adverse events will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0).	through study completion, up to 1 year
Secondary	Progression-free survival (PFS)	Evaluation the time to progression during and after the treatment.	through disease progression, up to 3 years
Secondary	Durable response rate (DRR)	Evaluation the length of time after a partial or complete response.	for 1 year
Secondary	1 year survival rate	Determine the 1 year survival rate of patient who received treatment.	at 1 year